FDA Publishes Draft Guidelines for Biosimilar Product Development


The U.S. Food and Drug Administration published its long-awaited draft guidance on the development of biosimilar products today (see FDA press release), taking a significant step toward the utilization of § 351(k) of the Public Health Service Act (amended by the Biologics Price Competition and Innovation Act (BPCIA)).  Section 351(k) creates a biologics pathway that is reminiscent of the pathway set forth by the Hatch-Waxman Act for small molecule drugs.  The FDA promised that it would release the guidance materials by the end of 2011, but failed to meet this deadline, most likely due to the complexities of the many issues surrounding biosimilar products.  The agency indicates that these guidance documents provide the FDA's current thinking on key scientific and regulatory factors involved in submitting applications for biosimilar products.  As expected, the FDA is seeking public comment on each of draft guidance documents within 60 days of the notice of publication in the Federal Register.

The BPCIA and section 351(k) have been in force since March 2010.  However, without any indication as to how the statute will be implemented by the FDA, the pathway has not gained much traction as an alternative to filing a full Biologics License Application (BLA) for a biologic under the PHSA (42 U.S.C. § 262).  Today's guidance documents provide some direction to companies involved in biosimilar development regarding the factors the FDA will use to evaluate whether to grant a license to their biosimilar products in the United States, despite the draft status of the guidance documents.  Now the biologics industry awaits public notification of the first 351(k) application filing, which under the statute, would set in motion a complex exchange of documents pertaining to the biologic, eventually progressing to litigation between the reference drug BLA holder and the 351(k) biosimilar applicant.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:


McDonnell Boehnen Hulbert & Berghoff LLP on:

Popular Topics
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.